These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16143163)

  • 1. Gemcitabine plus paclitaxel in breast cancer.
    Yardley DA
    Semin Oncol; 2005 Aug; 32(4 Suppl 6):S14-21. PubMed ID: 16143163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
    Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
    Trials; 2015 Dec; 16():575. PubMed ID: 26673577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
    Sledge GW
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):33-5. PubMed ID: 14768403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer.
    Sledge GW
    Semin Oncol; 2003 Apr; 30(2 Suppl 3):19-21. PubMed ID: 12722021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.
    Delfino C; Caccia G; Riva Gonzáles L; Mickiewicz E; Rodger J; Balbiani L; Flores Morales D; Zori Comba A; Brosio C
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):22-5. PubMed ID: 14768401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
    Park YH; Im SA; Kim SB; Sohn JH; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim JY; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH;
    Eur J Cancer; 2017 Nov; 86():385-393. PubMed ID: 29100193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
    Murad AM
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and paclitaxel in metastatic breast cancer: a review.
    Colomer R
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):8-12. PubMed ID: 15685819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience.
    O'Shaughnessy J
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):15-21. PubMed ID: 14768400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer.
    Zielinski CC
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):36-40. PubMed ID: 14768404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
    Demiray M; Kurt E; Evrensel T; Kanat O; Arslan M; Saraydaroglu O; Ercan I; Gonullu G; Gokgoz S; Topal U; Tolunay S; Tasdelen I; Manavoglu O
    Cancer Invest; 2005; 23(5):386-91. PubMed ID: 16193637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine combined with docetaxel in metastatic breast cancer.
    Fumoleau P
    Semin Oncol; 2003 Apr; 30(2 Suppl 3):15-8. PubMed ID: 12722020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.
    Xu B; Jiang Z; Kim SB; Yu S; Feng J; Malzyner A; Del Giglio A; Chung HC; Shen LJ; Pen DL
    Breast Cancer; 2011 Jul; 18(3):203-12. PubMed ID: 21465229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.
    Metro G; Fabi A; Russillo M; Papaldo P; De Laurentiis M; Ferretti G; Pellegrini D; Nuzzo C; Graziano V; Vici P; Introna M; Felici A; Cognetti F; Carlini P
    Anticancer Res; 2008; 28(2B):1245-58. PubMed ID: 18505062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the best schedule for administration of gemcitabine-taxane?
    Colomer R
    Cancer Treat Rev; 2005; 31 Suppl 4():S23-8. PubMed ID: 16360544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer.
    Tomao S; Romiti A; Tomao F; Di Seri M; Caprio G; Spinelli GP; Terzoli E; Frati L
    BMC Cancer; 2006 May; 6():137. PubMed ID: 16723016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial.
    Zhao Y; Lv F; Chen S; Wang Z; Zhang J; Zhang S; Cao J; Wang L; Cao E; Wang B; Hu X
    BMC Cancer; 2018 Oct; 18(1):1019. PubMed ID: 30348118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of gemcitabine activity in advanced breast cancer.
    Smith IE
    Semin Oncol; 2006 Jun; 33(3 Suppl 9):S19-23. PubMed ID: 16797378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.
    Im SA; Lee KS; Ro J; Lee ES; Kwon Y; Ahn JH; Ahn JS; Kim JH; Kang HS; Shin KH; Noh DY; Park IA; Kim SB; Im YH; Ha SW
    Breast Cancer Res Treat; 2012 Apr; 132(2):589-600. PubMed ID: 22094934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metastatic breast cancer: new chemotherapy regimens with taxanes].
    Lopez M
    Clin Ter; 2005; 156(6):311-5. PubMed ID: 16463568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.